Dusigitumab
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix. Its development has been discontinued.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1190942583 under CC BY-SA 4.0; modifications have been made.